
“Revolutionizing Sickle Cell Treatment: Beam Therapeutics Presents Promising Data from BEACON Trial at 2025 ASTCT and CIBMTR Meetings”
Exciting Announcement from Beam Therapeutics Inc. Beam Therapeutics Inc. to Present Data at ASTCT and CIBMTR Meetings CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, has announced that the company will be presenting data from the BEACON Phase 1/2 clinical…